Seralutinib

XOMA Royalty acquires seralutinib, a Phase 3 asset for pulmonary arterial hypertension, adding to its portfolio. Developed by Gossamer Bio and Chiesi Farmaceutici, seralutinib could net XOMA up to $25 million in milestone payments and low to mid-single digit royalties. The acquisition marks XOMA's second whole-company purchase in 2024.

XOMA Royalty acquires Pulmokine for $20 million, gaining rights to seralutinib, a Phase 3 asset for pulmonary arterial hypertension. This adds seralutinib as XOMA's seventh Phase 3 royalty asset, with potential milestone payments up to $25 million and low to mid-single digit royalties on commercial sales.

The article reviews the evolution of clinical trial endpoints for pulmonary arterial hypertension (PAH), highlighting the shift from traditional measures like 6-minute walk distance to composite endpoints such as time to clinical worsening. It discusses the challenges in validating biomarkers as surrogate endpoints and the potential of novel trial designs, including platform trials, to improve efficiency. The importance of patient-reported outcomes, diversity in trial participation, and the use of artificial intelligence in trial design are also emphasized.